PDA1
MCID: PTN014
MIFTS: 60

Patent Ductus Arteriosus 1 (PDA1)

Categories: Blood diseases, Cardiovascular diseases, Fetal diseases, Genetic diseases, Rare diseases, Respiratory diseases

Aliases & Classifications for Patent Ductus Arteriosus 1

MalaCards integrated aliases for Patent Ductus Arteriosus 1:

Name: Patent Ductus Arteriosus 1 57 29
Patent Ductus Arteriosus 57 12 75 53 37 6 15 63 33
Patent Ductus Arteriosus, Susceptibility to 57 13
Ductus Arteriosus, Patent 12 44
Pda1 57 53
Pda 57 53
Patent Ductus Arteriosus - Persisting Type 72
Patent Ductus Arteriosus Familial 53
Patency of the Ductus Arteriosus 53
Ductus Arteriosus Patent 55
Patent Ductus Botalli 12

Characteristics:

OMIM:

57
Inheritance:
autosomal recessive


HPO:

32
patent ductus arteriosus 1:
Inheritance autosomal recessive inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:13832
KEGG 37 H01630
ICD9CM 35 747.0
MeSH 44 D004374
NCIt 50 C84492
SNOMED-CT 68 83330001
ICD10 33 Q25.0
MedGen 42 C4282128
UMLS 72 C0013274 C3495549

Summaries for Patent Ductus Arteriosus 1

OMIM : 57 Persistent patency of the ductus arteriosus, or patent ductus arteriosus (PDA), is the second most common congenital heart disease, affecting approximately 1 in 1,600 to 5,000 live births in the U.S. (Mitchell et al., 1971). In fetal life, the ductus arteriosus, a muscular artery, shunts blood from the pulmonary artery to the aorta, bypassing the lungs. Its abrupt closure at birth establishes the mature circulatory pattern and represents a dramatic example of vascular remodeling. Failure of this normal process results in persistent PDA, which left untreated can result in pulmonary hypertension and heart failure. Closure of the ductus is a complex process. Aspects of this process are regulated by oxygen tension and a decrease in levels of hormones such as prostaglandin E2. PDA occurring in preterm infants often closes spontaneously or in response to inhibitors of prostaglandin biosynthesis (Ramsay et al., 1987). Term PDA typically has not been regarded as a genetic disorder, because it most often occurs sporadically. Nonetheless, term PDA recurs among 5% of sibs of PDA cases (Polani and Campbell, 1960; Lamy et al., 1957), suggesting a genetic component to disease pathogenesis that has typically been presumed to be multifactorial. That single genes can influence this trait has been demonstrated by a mouse model of PDA resulting from disruption of the prostaglandin E2 receptor (Nguyen et al., 1997) and by rare syndromic forms of PDA such as Char syndrome (169100), an autosomal dominant disorder caused by mutations in the transcription factor TFAP2B (601601) (Mani et al., 2002). (607411)

MalaCards based summary : Patent Ductus Arteriosus 1, also known as patent ductus arteriosus, is related to char syndrome and pulmonary valve stenosis. An important gene associated with Patent Ductus Arteriosus 1 is INPP5E (Inositol Polyphosphate-5-Phosphatase E), and among its related pathways/superpathways are Vascular smooth muscle contraction and Heart Development. The drugs Poractant alfa and Beractant have been mentioned in the context of this disorder. Affiliated tissues include heart, lung and brain, and related phenotypes are patent ductus arteriosus and cardiovascular system

KEGG : 37
Patent ductus arteriosus (PDA) is a common congenital heart defect with both inherited and acquired causes. The ductus arteriosus (DA) is a fetal specific vascular connection between the main pulmonary artery and the aorta. After birth, the DA normally closes within the first several days of life. If present after the age of 3 month, this condition is known as PDA. PDA can cause significant problems, especially in premature infants. It can be associated with an increased incidence of chronic lung disease, intraventricular hemorrhage, and necrotizing enterocolitis. Clinicians may choose to treat the PDA in an attempt to minimize the risk of these complications. Prostaglandin inhibition using indomethacin or ibuprofen is the standard strategy to close the DA. Surgical closure of the DA is an alternative option. Autosomal dominant forms of PDA caused by mutation in the TFAP2B and PRDM6 gene has been reported. PDA has been reported in a few subjects with thoracic aortic aneurysm and rare genetic variants in MYH11 and ACTA2.

PubMed Health : 63 About patent ductus arteriosus: Patent ductus arteriosus (PDA) is a heart problem that affects some babies soon after birth. In PDA, abnormal blood flow occurs between two of the major arteries connected to the heart. These arteries are the aorta and the pulmonary (PULL-mun-ary) artery. Before birth, these arteries are connected by a blood vessel called the ductus arteriosus. This blood vessel is a vital part of fetal blood circulation. Within minutes or up to a few days after birth, the ductus arteriosus closes. This change is normal in newborns. In some babies, however, the ductus arteriosus remains open (patent). The opening allows oxygen-rich blood from the aorta to mix with oxygen-poor blood from the pulmonary artery. This can strain the heart and increase blood pressure in the lung arteries.

Wikipedia : 75 Patent ductus arteriosus (PDA) is a medical condition in which the ductus arteriosus fails to close... more...

Related Diseases for Patent Ductus Arteriosus 1

Diseases in the Patent Ductus Arteriosus 1 family:

Patent Ductus Arteriosus 2 Patent Ductus Arteriosus 3

Diseases related to Patent Ductus Arteriosus 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 479)
# Related Disease Score Top Affiliating Genes
1 char syndrome 32.2 TFAP2B TFAP2A NKX2-5 ACTA2
2 pulmonary valve stenosis 31.4 PTPN11 GATA4
3 tricuspid valve insufficiency 31.4 PTPN11 NPPB
4 aortic valve disease 1 31.4 NPPB NKX2-5 ACTA2
5 tetralogy of fallot 31.4 PTPN11 NPPB NKX2-5 GATA6 GATA4
6 atrioventricular block 31.1 NPPB NKX2-5 GATA4
7 heart septal defect 31.1 NKX2-5 GATA6 GATA4
8 partial atrioventricular canal 31.0 GATA6 GATA4
9 atrioventricular septal defect 31.0 NKX2-5 GATA6 GATA4
10 hypertelorism 30.9 TFAP2A PTPN11 NSD1
11 ventricular septal defect 30.7 NPPB NKX2-5 GATA6 GATA4
12 patent foramen ovale 30.6 TLL1 PTPN11 NKX2-5 GATA6 GATA4 ELMOD2
13 heart disease 30.5 TFAP2B PTPN11 NPPB NKX2-5 GATA6 GATA4
14 double outlet right ventricle 30.1 NKX2-5 GATA6 GATA4
15 atrial heart septal defect 30.0 TLL1 NKX2-5 GATA6 GATA4 ELMOD2
16 patent ductus arteriosus and bicuspid aortic valve with hand anomalies 12.8
17 intestinal pseudoobstruction with patent ductus arteriosus and natal teeth 12.7
18 congenital patent ductus arteriosus aneurysm 12.6
19 pulmonary artery coming from patent ductus arteriosus 12.6
20 multisystemic smooth muscle dysfunction syndrome 12.5
21 fontaine progeroid syndrome 12.3
22 aortic aneurysm, familial thoracic 4 12.2
23 subvalvular aortic stenosis 11.9
24 heterotaxy, visceral, 1, x-linked 11.7
25 microcephaly, facial dysmorphism, renal agenesis, and ambiguous genitalia syndrome 11.7
26 ramos arroyo clark syndrome 11.7
27 right pulmonary artery, anomalous origin of, familial 11.6
28 natal teeth, intestinal pseudoobstruction and patent ductus 11.6
29 arterial duct anomaly 11.6
30 premature closure of the arterial duct 11.6
31 femoral-facial syndrome 11.5
32 hypertelorism, teebi type 11.5
33 mcdonough syndrome 11.5
34 hypertrophic osteoarthropathy, primary, autosomal recessive, 1 11.5
35 restrictive dermopathy, lethal 11.5
36 periventricular nodular heterotopia 1 11.5
37 heart defects, congenital, and other congenital anomalies 11.5
38 axenfeld-rieger syndrome, type 3 11.5
39 retinal dystrophy, iris coloboma, and comedogenic acne syndrome 11.5
40 nephronophthisis 16 11.5
41 congenital heart defects, multiple types, 4 11.5
42 nephronophthisis 20 11.5
43 congenital heart defects, multiple types, 5 11.5
44 cardiac, facial, and digital anomalies with developmental delay 11.5
45 chromosome 15, trisomy mosaicism 11.5
46 manouvrier syndrome 11.5
47 mcgillivray syndrome 11.5
48 chops syndrome 11.4
49 cantu syndrome 11.3
50 pancreatic cancer 11.3

Graphical network of the top 20 diseases related to Patent Ductus Arteriosus 1:



Diseases related to Patent Ductus Arteriosus 1

Symptoms & Phenotypes for Patent Ductus Arteriosus 1

Human phenotypes related to Patent Ductus Arteriosus 1:

32
# Description HPO Frequency HPO Source Accession
1 patent ductus arteriosus 32 HP:0001643

Symptoms via clinical synopsis from OMIM:

57
Cardiovascular Vascular:
patent ductus arteriosus

Clinical features from OMIM:

607411

MGI Mouse Phenotypes related to Patent Ductus Arteriosus 1:

46 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.31 ACTA2 FLNA GATA4 GATA6 MYH11 NKX2-5
2 homeostasis/metabolism MP:0005376 10.25 AVPR2 ELMOD2 FLNA GATA4 GATA6 MYH11
3 cellular MP:0005384 10.22 FLNA GATA4 GATA6 INPP5E MYH11 NKX2-5
4 growth/size/body region MP:0005378 10.22 AVPR2 FLNA GATA4 GATA6 INPP5E MYH11
5 hematopoietic system MP:0005397 10.16 AVPR2 FLNA GATA4 GATA6 NKX2-5 PTGER4
6 mortality/aging MP:0010768 10.13 AVPR2 FLNA GATA4 GATA6 INPP5E MYH11
7 digestive/alimentary MP:0005381 10.11 FLNA GATA4 INPP5E MYH11 NKX2-5 PTPN11
8 embryo MP:0005380 10.1 GATA4 GATA6 INPP5E NKX2-5 NSD1 PRDM6
9 integument MP:0010771 10.1 AVPR2 GATA4 MYH11 NKX2-5 PRDM6 PTGER4
10 limbs/digits/tail MP:0005371 9.91 GATA4 GATA6 INPP5E PTPN11 TFAP2A TFAP2B
11 liver/biliary system MP:0005370 9.87 FLNA GATA4 GATA6 PTGER4 PTPN11 TLL1
12 muscle MP:0005369 9.81 ACTA2 GATA4 GATA6 MYH11 NKX2-5 PTGER4
13 respiratory system MP:0005388 9.65 FLNA GATA4 GATA6 MYH11 NKX2-5 PRDM6
14 skeleton MP:0005390 9.23 ELMOD2 FLNA GATA4 INPP5E PTGER4 PTPN11

Drugs & Therapeutics for Patent Ductus Arteriosus 1

PubMed Health treatment related to Patent Ductus Arteriosus 1: 63

Patent ductus arteriosus (PDA) is treated with medicines, catheter-based procedures, and surgery. The goal of treatment is to close the PDA. Closure will help prevent complications and reverse the effects of increased blood volume. Small PDAs often close without treatment. For full-term infants, treatment is needed if the PDA is large or causing health problems. For premature infants, treatment is needed if the PDA is causing breathing problems or heart problems. Talk with your child's doctor about treatment options and how your family prefers to handle treatment decisions.

Drugs for Patent Ductus Arteriosus 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 130)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1 Poractant alfa Approved Phase 4 129069-19-8
2 Beractant Approved Phase 4 108778-82-1
3 Respiratory System Agents Phase 4
4 Pulmonary Surfactants Phase 4
5
tannic acid Approved Phase 3 1401-55-4
6
Benzocaine Approved, Investigational Phase 3 94-09-7, 1994-09-7 2337
7
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
8
Acetaminophen Approved Phase 3 103-90-2 1983
9
Fenoldopam Approved Phase 2, Phase 3 67227-56-9, 67227-57-0 3341
10
Tocopherol Approved, Investigational Phase 3 1406-66-2, 54-28-4 14986
11
Vitamin E Approved, Nutraceutical, Vet_approved Phase 3 59-02-9 14985
12
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 22737-96-8, 11103-57-4, 68-26-8 9904001 445354
13
Vitamin D Approved, Nutraceutical, Vet_approved Phase 3 1406-16-2
14 Tocotrienol Investigational Phase 3 6829-55-6
15 lysine Phase 3
16 Analgesics, Opioid Phase 3
17 Anesthetics, Intravenous Phase 3
18 Narcotics Phase 3
19 Adjuvants, Anesthesia Phase 3
20 Central Nervous System Depressants Phase 3
21 Anesthetics, General Phase 3
22 Anesthetics Phase 3
23 Antipyretics Phase 3
24 Vasodilator Agents Phase 2, Phase 3
25 Antihypertensive Agents Phase 2, Phase 3
26 Dopamine agonists Phase 2, Phase 3
27 Tocotrienols Phase 3
28 Vitamins Phase 3
29 Retinol palmitate Phase 3
30 Nutrients Phase 3
31 Tocopherols Phase 3
32 retinol Phase 3
33 Micronutrients Phase 3
34 Trace Elements Phase 3
35 Calciferol Phase 3
36 Pharmaceutical Solutions Phase 2, Phase 3
37
Pentoxifylline Approved, Investigational Phase 2 6493-05-6 4740
38
Tadalafil Approved, Investigational Phase 2 171596-29-5 110635
39
Fludrocortisone Approved, Investigational Phase 2 127-31-1 31378
40
Azithromycin Approved Phase 2 83905-01-5 447043 55185
41
Erythromycin Approved, Investigational, Vet_approved Phase 2 114-07-8 441411 12560
42
Meclocycline Experimental, Investigational Phase 2 2013-58-3 5480760
43 Radiation-Protective Agents Phase 2
44 Platelet Aggregation Inhibitors Phase 2
45 Antibodies Phase 1, Phase 2
46 Immunologic Factors Phase 1, Phase 2
47 gamma-Globulins Phase 1, Phase 2
48 Immunoglobulins Phase 1, Phase 2
49 Immunoglobulins, Intravenous Phase 1, Phase 2
50 Rho(D) Immune Globulin Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 149)
# Name Status NCT ID Phase Drugs
1 Comparison Between the Effect of Oral Paracetamol Versus Oral Ibuprofen in the Treatment of Patent Ductus Arteriosus in Preterm and Low Birth Weight Infants Unknown status NCT03265782 Phase 4 ibuprofen;paracetamol
2 Serum Level Measurement of Oral Paracetamol and Oral Ibuprofen Unknown status NCT01544972 Phase 4 Oral paracetamol;Oral ibuprofen
3 THE EFFECT OF SUSTAINED LUNG INFLATION MANEUVER APPLIED THROUGH NASAL PRONG ON EARLY AND LATE RESPIRATORY MORBIDITIES IN PRETERM INFANTS Unknown status NCT02887924 Phase 4
4 Oral Paracetamol Versus Oral Ibuprofen Treatment Completed NCT01536158 Phase 4 Oral paracetamol;Oral ibuprofen
5 Ibuprofen and Renal Function in Premature Infants Completed NCT00217191 Phase 4 Ibuprofen
6 Randomized Pilot Study Comparing Oral Ibuprofen With Intravenous Ibuprofen in Very Low Birth Weight Infants With Patent Ductus Arteriosus Completed NCT00642330 Phase 4 oral ibuprofen;intravenous ibuprofen
7 Multicentre Randomised Controlled Trial of Minimally-invasive Surfactant Therapy in Preterm Infants 25-28 Weeks Gestation on Continuous Positive Airways Pressure Recruiting NCT02140580 Phase 4
8 Safety and Efficacy of an Optimized Ibuprofen Dosing Regimen Versus Standard Dosing for Pharmacologic Closure of Patent Ductus Arteriosus Terminated NCT00961753 Phase 4 optimized ibuprofen;Standard Ibuprofen
9 Phase 4 Study of Curosurf (Poractant) and Survanta (Beractant) Surfactant Treatment in Very Premature Infants With Respiratory Distress Syndrome. Terminated NCT00767039 Phase 4 Survanta (beractant);Curosurf (poractant)
10 A Randomised Controlled Trial Comparing Ibuprofen And Indomethacin For The Treatment Of The Patent Ductus Arteriosus In Very Premature Infants Withdrawn NCT00470743 Phase 4 Ibuprofen;Indomethacin
11 Adding Paracetamol to Ibuprofen for Treatment of Patent Ductus Arteriosus in Preterm Infants: A Pilot, Double Blind, Randomized, Placebo-control Trial Unknown status NCT02002741 Phase 2, Phase 3 Paracetamol;Placebo
12 Paracetamol Versus Ibuprofen for Patent Ductus Arteriosus Closure in Preterm Infants. A Prospective, Randomized, Controlled, Double Blind, Multicenter Clinical Trial. Unknown status NCT02056223 Phase 2, Phase 3 Intravenous paracetamol;Intravenous ibuprofen
13 Nasal Intermittent Mandatory Ventilation Versus Continuous Positive Airway Pressure After Extubation of Very Low Birth Weight Infants of the NEOCOSUR Network. Unknown status NCT01778829 Phase 3
14 Randomized, Double-Blind Study of Ibuprofen L-Lysine Intravenous Solution in Premature Infants for the Early Treatment of Patent Ductus Arteriosus Completed NCT00440804 Phase 3 ibuprofen l-lysine iv solution (NeoProfen (R) )
15 Impact of Early Targeted Ibuprofene Treatment of Patent Ductus Arteriosus (PDA) on Long Term Neurodevelopmental Outcome in Very Premature Infants (TRIOCAPI) Completed NCT01630278 Phase 3 Ibuprofen;Placebo
16 Trial of Indomethacin Prophylaxis in Preterm Infants (TIPP) Completed NCT00009646 Phase 3 indomethacin;Indomethacin;Placebo
17 Comparison of Intravenous Ibuprofen vs. Continuous Indomethacin in the Treatment of Patent Ductus Arteriosus Completed NCT00485160 Phase 3 Continuous indomethacin;ibuprofen
18 Randomised Controlled Clinical Trial of Echocardiographically Guided Versus Standard Ibuprofen Treatment for Patent Ductus Arteriosus: a Pilot Study Completed NCT01593163 Phase 3 Ibuprofen EchoG;Standard ibuprofen treatment
19 Management of Patent Ductus in Premature Infants Completed NCT00000494 Phase 3 indomethacin
20 High-dose Ibuprofen for Patent Ductus Arteriosus in Extremely Preterm Infants: a Randomized Controlled Study Completed NCT01243996 Phase 2, Phase 3 Ibuprofen
21 Liberal Versus Restrictive Platelet Transfusion for Treatment of Hemodynamically Significant Patent Ductus Arteriosus in Thrombocytopenic Preterm Neonates- A Randomized Open Label, Controlled Trial Completed NCT03022253 Phase 3 Paracetamol;Ibuprofen
22 L-Thyroxine Supplementation for Preterm Newborns Less Than 32 Weeks of Gestation With Transient Hypothyroxinemia of Prematurity: a Prospective Randomized Double-blind Trial Completed NCT01306227 Phase 3 L-Thyroxine;water
23 Efficacy and Safety of Continuous Infusion of Fentanyl for Pain Control in Preterm Newborn on Mechanical Ventilation Completed NCT00571636 Phase 3 Fentanyl;5% glucose solution
24 Management of the Patent Ductus Arteriosus in Premature Infants Trial (PDA Trial) Recruiting NCT03456336 Phase 3
25 Paracetamol Versus Ibuprofen in Premature Infants With Hemodynamically Significant Patent Ductus Arteriosus: a Randomized Clinical Trial Recruiting NCT04037514 Phase 3 Paracetamol;Ibuprofen
26 Comparison of the Efficacy of IV Acetaminophen Versus IV Indomethacin in Treatment of Hemodynamically Significant PDA in VLBW Infants Recruiting NCT03537144 Phase 3 Indomethacin;Acetaminophen
27 Fenoldopam to Prevent Renal Dysfunction in Indomethacin Treated Preterm Infants Recruiting NCT02620761 Phase 2, Phase 3 Fenoldopam;0.9%NS
28 Effects of Fat-soluble Vitamins Supplementation in Early Life on Common Complications and Neural Development in Very Low Birth Weight Infants Recruiting NCT03876704 Phase 3 High dose of fat-Soluble Vitamin;Conventional dose of fat-Soluble Vitamin
29 Alternative Acetaminophen Treatment of the Hemodynamivally Significant Patent Ductus Arteriosus in Preterm Neonates Who Are Not Candidates for Enteral Administration: A Pilot Study Not yet recruiting NCT03604796 Phase 2, Phase 3 Rectal Solution;Intravenous Infusion
30 An Escalating Dose Indomethacin for the Treatment of Persistent Patent Ductus Arteriosus (PDA) In Preterm Infants- A Randomized Pilot Study Terminated NCT00750581 Phase 2, Phase 3 Indomethacin
31 New Therapeutic Approaches to the Resistant Patent Ductus Arteriosus (PDA) in Low Birth Weight Neonates Unknown status NCT00616382 Phase 2 Indomethacin;Pentoxifylline
32 TIME TO RE-EVALUATE THE KINDER GENTLER APPROACH TO PATENT DUCTUS ARTERIOSUS (PDA) IN THE PRETERM NEONATE Unknown status NCT02819414 Phase 2 Paracetamol drops
33 Paracetamol in the Treatment of Patent Ductus Arteriosus in the Premature Neonate Unknown status NCT01291654 Phase 2 Paracetamol;NSAID;D5W
34 The Best Treatment Strategy: Surgical Versus Pharmacological, to Close the Ductus Arteriosus Persistent in Preterm Infants. A Randomized Controlled Trial Unknown status NCT02602054 Phase 2 Control group
35 Comparison of Oral and Intravenous Ibuprofen for Treatment of Patent Ductus Arteriosus in Extremely Premature Infants: A Randomized Controlled Trial Unknown status NCT01149564 Phase 1, Phase 2 iv ibuprofen;oral ibuprofen
36 Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Unknown status NCT02230163 Phase 1, Phase 2
37 Efficacy and Safety of Paracetamol in Comparison to Ibuprofen for Patent Ductus Arteriosus Treatment in Preterm Infants: A Randomized, Open Label, Comparator-controlled, Prospective Study Completed NCT02422966 Phase 2 Paracetamol;Ibuprofen
38 Early Treatment Versus Delayed Conservative Treatment of the Patent Ductus Arteriosus in Preterm infants-a Multicenter Trial Completed NCT01958320 Phase 2 NSAID
39 Comparison of 2 Different Indomethacin Dosing Protocols to Treat Infants Delivered at <28 Weeks Gestation With a Persistent Patent Ductus Arteriosus Completed NCT00187447 Phase 2 indomethacin (two different dosing regimens)
40 The Preterm Infants' Paracetamol Study Completed NCT01938261 Phase 2 paracetamol;0.45 % saline solution
41 Clinical Efficacy of Phosphodiesterase-5 Inhibitor Tadalafil in Eisenmenger Syndrome - A Randomised, Placebo Controlled, Double Blind, Crossover Study Completed NCT01200732 Phase 2 Tadalafil, placebo
42 Single Center, Randomized, Double Blind, Placebo Controlled Trial to Evaluate the Safety and Efficacy of Acetaminophen in Preterm Infants Used in Combination With Ibuprofen for Closure of the Ductus Arteriosus Recruiting NCT03701074 Phase 2 Ibuprofen and acetaminophen;Ibuprofen and placebo
43 Extremely Low Gestational Age Infants' Paracetamol Study: a Randomized Trial Recruiting NCT03641209 Phase 1, Phase 2 Paracetamol 10mg/mL infusion solution
44 Impact of the Administration of Fludrocortisone on Fluid and Electrolyte Balance in Very Premature Infants: Pilot Study Recruiting NCT03001089 Phase 2 Oral Fludrocortisone (enteral);Placebo Oral Tablet
45 Efficacy and Safety of No Treatment Compared With Oral Ibuprofen Treatment for Patent Ductus Arteriosus in Preterm Infants: a Randomized, Double-blind, Placebo-controlled, Non-inferiority Clinical Trial Active, not recruiting NCT02128191 Phase 2 Oral ibuprofen;Normal saline
46 A Phase IIb Randomized, Placebo-controlled, Double-blind Trial of Azithromycin to Eradicate Ureaplasma Respiratory Tract Infection in Preterm Infants Active, not recruiting NCT01778634 Phase 2 Azithromycin;Placebo
47 Monotherapy (Ibuprofen) vs. Combination Therapy (Ibuprofen and Acetaminophen) in the Management of Patent Ductus Arteriosus in Premature Infants: A Randomized Controlled Trial Not yet recruiting NCT04026464 Phase 2 Intravenous Ibuprofen;Intravenous Ibuprofen + Oral Acetaminophen
48 Pharmacokinetics and Pharmacodynamics of Indomethacin Used for PDA Treatment in Extremely Preterm Neonates <27 Weeks Gestational Age Not yet recruiting NCT04025177 Phase 2 Indomethacin Injection
49 Usefulness of Extracorporeal Removal of sFlt-1 in Women With Severe Preeclampsia at Less Than 26 Weeks' Gestation Terminated NCT02286284 Phase 2
50 Phase 2 Study of Oral Probiotics Reduce the Incidence and Severity of Necrotizing Enterocolitis for Very Low Birth Weight Infants -Multi-Center Randomized Control Trial Terminated NCT00540033 Phase 2

Search NIH Clinical Center for Patent Ductus Arteriosus 1

Inferred drug relations via UMLS 72 / NDF-RT 51 :


Alprostadil
Ibuprofen
Indomethacin

Cochrane evidence based reviews: ductus arteriosus, patent

Genetic Tests for Patent Ductus Arteriosus 1

Genetic tests related to Patent Ductus Arteriosus 1:

# Genetic test Affiliating Genes
1 Patent Ductus Arteriosus 1 29

Anatomical Context for Patent Ductus Arteriosus 1

MalaCards organs/tissues related to Patent Ductus Arteriosus 1:

41
Heart, Lung, Brain, Kidney, Testes, Smooth Muscle, Thyroid

Publications for Patent Ductus Arteriosus 1

Articles related to Patent Ductus Arteriosus 1:

(show top 50) (show all 7928)
# Title Authors PMID Year
1
Genetics of patent ductus arteriosus susceptibility and treatment. 38 8
22414880 2012
2
Finding genetic contributions to sporadic disease: a recessive locus at 12q24 commonly contributes to patent ductus arteriosus. 38 8
12409608 2002
3
Response of the patent ductus arteriosus to indomethacin treatment. 38 8
3812411 1987
4
The prostaglandin receptor EP4 triggers remodelling of the cardiovascular system at birth. 8
9363893 1997
5
Congenital heart disease in 56,109 births. Incidence and natural history. 8
5102136 1971
6
Factors in the causation of persistent ductus arteriosus. 8
13736684 1960
7
Genetic and non-genetic factors in the etiology of congenital heart disease: a study of 1188 cases. 8
13410899 1957
8
B-type natriuretic peptide concentrations to guide treatment of patent ductus arteriosus. 9 38
18981033 2009
9
Longitudinal changes of brain-type natriuretic peptide in preterm neonates. 9 38
16740863 2006
10
Role of plasma B-type natriuretic peptide in screening for hemodynamically significant patent ductus arteriosus in preterm neonates. 9 38
16222347 2005
11
The use of a bedside assay for plasma B-type natriuretic peptide as a biomarker in the management of patent ductus arteriosus in premature neonates. 9 38
16027692 2005
12
Efficacy and safety of oral paracetamol versus oral ibuprofen for closure of patent ductus arteriosus in preterm infants: a randomized controlled trial. 38
29695206 2019
13
The effect of hemodynamically significant patent ductus arteriosus on acute kidney injury and systemic hypertension in extremely low gestational age newborns. 38
29642731 2019
14
Exploration of potential biochemical markers for persistence of patent ductus arteriosus in preterm infants at 22-27 weeks' gestation. 38
30287890 2019
15
Insights image for exploration of potential biochemical markers for persistence of patent ductus arteriosus in preterm infants at 22-27 weeks' gestation. 38
31195403 2019
16
Bilateral Congenital Corneal Opacities as an Early-Onset Ocular Feature of Kabuki Syndrome. 38
30950893 2019
17
Cannabis Teratology Explains Current Patterns of Coloradan Congenital Defects: The Contribution of Increased Cannabinoid Exposure to Rising Teratological Trends. 38
31288542 2019
18
Paracetamol treatment for patent ductus arteriosus: practice and attitudes in Australia and New Zealand. 38
29562792 2019
19
Early haemodynamically significant patent ductus arteriosus does not predict future persistence in extremely preterm infants. 38
30748032 2019
20
Patent ductus arteriosus in preterm infants born at 23-24 weeks' gestation: Should we pay more attention? 38
31212222 2019
21
Oral ibuprofen is superior to oral paracetamol for patent ductus arteriosus in very low and extremely low birth weight infants. 38
31374055 2019
22
You "Cantu": Multidisciplinary Collaboration Resulting in Successful Orthognathic Surgery. 38
31401848 2019
23
Assessment of intracardiac and extracardiac anomalies associated with coarctation of aorta and interrupted aortic arch using dual-source computed tomography. 38
31406129 2019
24
A pilot randomised clinical trial of 670 nm red light for reducing retinopathy of prematurity. 38
31430763 2019
25
Outcomes of singleton small for gestational age preterm infants exposed to maternal hypertension: a retrospective cohort study. 38
31086284 2019
26
Prophylactic Sildenafil in Preterm Infants at Risk of Bronchopulmonary Dysplasia: A Pilot Randomized, Double-Blinded, Placebo-Controlled Trial. 38
31414269 2019
27
Glibenclamide treatment in a Cantú syndrome patient with a pathogenic ABCC9 gain-of-function variant: Initial experience. 38
31175705 2019
28
Circumferential and radial deformation assessment in premature infants: Ready for primetime? 38
31385346 2019
29
Oral vitamin A supplementation in very low birth weight neonates: a randomized controlled trial. 38
31209560 2019
30
Severe Perinatal Bronchomalacia in Newborn with Patent Ductus Arteriosus. 38
31425656 2019
31
Dosing and Safety of Off-label Use of Caffeine Citrate in Premature Infants. 38
31101409 2019
32
Larger Dose Reductions of Vancomycin Required in Neonates with Patent Ductus Arteriosus Receiving Indomethacin versus Ibuprofen. 38
31182538 2019
33
Thoracotomy versus sternotomy for patent ductus arteriosus closure in preterm neonates. 38
31408645 2019
34
Path Toward Proactive Therapy for Patent Ductus Arteriosus. 38
31433488 2019
35
Neonatal ibuprofen exposure and bronchopulmonary dysplasia in extremely premature infants. 38
31391526 2019
36
Voice hoarseness in a patient with underlying Eisenmenger's syndrome: a case report. 38
31426857 2019
37
NT-proBNP as an Early Marker of Diastolic Ventricular Dysfunction in Very-Low-Birth-Weight Infants. 38
31175403 2019
38
Changes in hemodynamics, cerebral oxygenation and cerebrovascular reactivity during the early transitional circulation in preterm infants. 38
31029059 2019
39
Discovering Pain in Newborn Infants. 38
31233407 2019
40
Percutaneous patent ductus arteriosus closure using intraprocedural mixed reality visualization of 3D computed tomography angiography data: first-in-man experience. 38
31220228 2019
41
Patent Ductus Arteriosus and the Effects of Its Late Closure in Preterm Infants with Severe Bronchopulmonary Dysplasia. 38
31269508 2019
42
Predictors of Early Extubation after Patent Ductus Arteriosus Ligation among Infants Born Extremely Preterm Dependent on Mechanical Ventilation. 38
31279574 2019
43
Cerebral perfusion and assessing hemodynamic significance for patent ductus arteriosus using near infrared red spectroscopy in very low birth weight infants. 38
31303077 2019
44
Endovascular Therapy of a Giant Renal Artery Aneurysm Combined With High-Flow Renal Arteriovenous Fistula Using a Patent Ductus Arteriosus Occluder. 38
30802564 2019
45
Prophylactic low-dose paracetamol administration associated with lowered rate of patent ductus arteriosus in preterm infants - Impact on outcome and pain perception. 38
31345732 2019
46
Birth weight discordance in very low birth weight twins: mortality, morbidity, and neurodevelopment. 38
31312035 2019
47
Association between severe retinopathy of prematurity and postnatal weight gain in very low-birth weight infants at Chiang Mai University Hospital, Thailand. 38
31272307 2019
48
A novel missense mutation in TFAP2B associated with Char syndrome and central diabetes insipidus. 38
31012281 2019
49
Relationship between pulmonary artery acceleration time and pulmonary artery pressures in infants. 38
31260138 2019
50
Feasibility of Device Closure for Multiple Atrial Septal Defects With an Inferior Sinus Venosus Defect: Procedural Planning Using Three-Dimensional Printed Models. 38
31402125 2019

Variations for Patent Ductus Arteriosus 1

ClinVar genetic disease variations for Patent Ductus Arteriosus 1:

6 (show all 11)
# Gene Variation Type Significance SNP ID GRCh37 Pos GRCh38 Pos
1 PTPN11 NM_002834.4(PTPN11): c.184T> G (p.Tyr62Asp) single nucleotide variant Pathogenic rs121918460 12:112888168-112888168 12:112450364-112450364
2 46;XX;ins(5;6)(p13;p24p25)dn Translocation Pathogenic
3 46;XY;inv(6)(p22q13)dn inversion Pathogenic
4 46;XX;ins(2;9)(q24.3;p22.1p24.3)dn Translocation Pathogenic
5 INPP5E NM_019892.6(INPP5E): c.1132C> T (p.Arg378Cys) single nucleotide variant Pathogenic/Likely pathogenic rs121918130 9:139327634-139327634 9:136433182-136433182
6 TNFRSF13B NM_012452.2(TNFRSF13B): c.310T> C (p.Cys104Arg) single nucleotide variant risk factor rs34557412 17:16852187-16852187 17:16948873-16948873
7 46;XX;inv(7)(q21.2q34) inversion Likely pathogenic
8 46;XY;t(2;14)(p22;q24.3)dn Translocation Likely pathogenic
9 HYDIN NM_001270974.2(HYDIN): c.10816G> T (p.Gly3606Ter) single nucleotide variant Likely pathogenic 16:70908340-70908340 16:70874437-70874437
10 HYDIN NM_001270974.2(HYDIN): c.6631G> A (p.Asp2211Asn) single nucleotide variant Uncertain significance 16:70977753-70977753 16:70943850-70943850
11 VANGL1 NM_138959.3(VANGL1): c.523C> T (p.Arg175Trp) single nucleotide variant Uncertain significance rs142594314 1:116206600-116206600 1:115663979-115663979

Expression for Patent Ductus Arteriosus 1

Search GEO for disease gene expression data for Patent Ductus Arteriosus 1.

Pathways for Patent Ductus Arteriosus 1

Pathways related to Patent Ductus Arteriosus 1 according to KEGG:

37
# Name Kegg Source Accession
1 Vascular smooth muscle contraction hsa04270

Pathways related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 10.59 PTPN11 NKX2-5 GATA6 GATA4
2 10.47 NPPB NKX2-5 GATA4
3 9.93 NKX2-5 GATA4

GO Terms for Patent Ductus Arteriosus 1

Biological processes related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.88 TFAP2B TFAP2A NKX2-5 GATA6 FLNA
2 negative regulation of transcription, DNA-templated GO:0045892 9.85 TFAP2B TFAP2A PRDM6 NKX2-5 GATA6
3 retina layer formation GO:0010842 9.52 TFAP2B TFAP2A
4 transcription by RNA polymerase II GO:0006366 9.51 TFAP2B GATA6
5 positive regulation of transcription, DNA-templated GO:0045893 9.5 TFAP2B TFAP2A NSD1 NKX2-5 GATA6 GATA4
6 cardiac muscle tissue development GO:0048738 9.49 NKX2-5 GATA6
7 positive regulation of urine volume GO:0035810 9.43 TFAP2B NPPB
8 atrial septum morphogenesis GO:0060413 9.4 NKX2-5 GATA4
9 heart development GO:0007507 9.37 PTPN11 NKX2-5
10 cardiac muscle cell differentiation GO:0055007 9.33 NKX2-5 GATA6 GATA4
11 cardiac ventricle morphogenesis GO:0003208 9.32 NKX2-5 GATA4
12 intestinal epithelial cell differentiation GO:0060575 9.26 GATA6 GATA4
13 positive regulation of cardioblast differentiation GO:0051891 8.8 NKX2-5 GATA6 GATA4

Molecular functions related to Patent Ductus Arteriosus 1 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 DNA-binding transcription factor activity, RNA polymerase II-specific GO:0000981 9.98 ZNF213 TFAP2B TFAP2A PRDM6 NKX2-5 GATA6
2 DNA-binding transcription factor activity GO:0003700 9.85 ZNF213 TFAP2B TFAP2A NKX2-5 GATA6 GATA4
3 transcription factor binding GO:0008134 9.76 NKX2-5 GATA6 GATA4 FLNA
4 RNA polymerase II regulatory region sequence-specific DNA binding GO:0000977 9.71 TFAP2B TFAP2A PRDM6 GATA4
5 chromatin binding GO:0003682 9.65 TFAP2B TFAP2A NSD1 NKX2-5 GATA6
6 sequence-specific DNA binding GO:0043565 9.63 TFAP2B TFAP2A PRDM6 NKX2-5 GATA6 GATA4
7 transcription regulatory region DNA binding GO:0044212 9.62 TFAP2A NKX2-5 GATA6 GATA4
8 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.43 TFAP2B TFAP2A NSD1 NKX2-5 GATA6 GATA4
9 enhancer sequence-specific DNA binding GO:0001158 8.62 TFAP2B GATA4

Sources for Patent Ductus Arteriosus 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
Content
Loading form....